KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Esperion Therapeutics (ESPR) Other Working Capital Changes (2018 - 2025)

Historic Other Working Capital Changes for Esperion Therapeutics (ESPR) over the last 8 years, with Q3 2025 value amounting to $6.4 million.

  • Esperion Therapeutics' Other Working Capital Changes rose 13881.56% to $6.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $15.6 million, marking a year-over-year increase of 43586.65%. This contributed to the annual value of -$16.9 million for FY2024, which is 17711.35% down from last year.
  • As of Q3 2025, Esperion Therapeutics' Other Working Capital Changes stood at $6.4 million, which was up 13881.56% from $10.8 million recorded in Q2 2025.
  • Esperion Therapeutics' 5-year Other Working Capital Changes high stood at $10.8 million for Q2 2025, and its period low was -$16.6 million during Q3 2024.
  • Moreover, its 5-year median value for Other Working Capital Changes was $2.4 million (2021), whereas its average is $1.5 million.
  • Its Other Working Capital Changes has fluctuated over the past 5 years, first tumbled by 50594.28% in 2024, then surged by 352634.92% in 2025.
  • Quarter analysis of 5 years shows Esperion Therapeutics' Other Working Capital Changes stood at $2.4 million in 2021, then tumbled by 122.38% to -$538000.0 in 2022, then soared by 1155.58% to $5.7 million in 2023, then tumbled by 215.51% to -$6.6 million in 2024, then skyrocketed by 198.22% to $6.4 million in 2025.
  • Its last three reported values are $6.4 million in Q3 2025, $10.8 million for Q2 2025, and $4.9 million during Q1 2025.